Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Paratek Earns Actavis Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Paratek Earns Actavis Milestone

Sarecycline advances to Phase III trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Paratek Pharmaceuticals, Inc. will receive a $4 million milestone payment from Actavis under the companies’ sarecycline (WC3035) development collaboration. Actavis has initiated Phase III trials of sarecycline in moderate to severe acne. Paratek is eligible for additional regulatory and commercialization milestones, including NDA acceptance, approval, and royalties on sales.
 
The companies entered the exclusive collaboration for sarecycline in July 2007. Paratek designed and developed sarecycline, which is a tetracycline-derived compound that, based on preclinical studies, demonstrates a narrow spectrum of antibacterial activity against relevant skin bacterial pathogens, offering a favorable tolerability profile compared to oral tetracycline antibiotics that are the current standard of care. Paratek retains the rights to develop and commercialize sarecycline in all territories outside the U.S.
 
“The commencement of the Phase III trials by our collaboration partner Actavis is a significant step forward towards the potential commercialization in the U.S. of our proprietary compound sarecycline. We believe that sarecycline has the potential to be an important new once-daily oral medication for the treatment of moderate to severe acne,” said Evan Loh president and chief medical officer Paratek.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics